ABSTRACT
OBJECTIVE:To evaluate clinical efficacy and the effect of pharmacoeconomics of two chemotherapeutic regimens for the first line treatment of advanced gastric cancer. METHODS:98 patients with advanced gastric cancer receiving SOX or FLO regimen as first line chemotherapy in our hospital were enrolled. According to chemotherapy grouping,short-term efficacy,toxic re-action and pharmacoeconomics effect were analyzed and compared between 2 groups. RESULTS:There were a total of 55 patients in SOX group,with effective rate of 38.18%;43 patients in FLO group,with effective rate of 32.56%;there was no statistical sig-nificance in effective rate between 2 groups(P>0.05). There was no statistical significance in toxicities between 2 groups,includ-ing nausea and vomiting,neurotoxicity and neutropenia(P>0.05). The total cost of FLO regimen group was 9 136.98 yuan,while that of SOX regimen group was 12 345.97 yuan. Using minimum cost method,FLO regimen was superior to SOX regimen regard-ing the economical index. CONCLUSIONS:SOX and FLO regimen have no significant difference for the first-line treatment of ad-vanced gastric cancer in terms of response rate and toxicities. Taking into account the parmocyeconomics,FOL regimen is superior to SOX regimen.